These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 28507750

  • 1. Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.
    Appleby RN, Bajor A, Gillberg PG, Graffner H, Simrén M, Ung KA, Walters J.
    United European Gastroenterol J; 2017 Apr; 5(3):380-388. PubMed ID: 28507750
    [Abstract] [Full Text] [Related]

  • 2. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
    Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, Basumani P, Bardhan KD, Walters JR.
    Aliment Pharmacol Ther; 2013 Oct; 38(8):967-76. PubMed ID: 23981126
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea.
    Pattni SS, Brydon WG, Dew T, Walters JR.
    Clin Transl Gastroenterol; 2012 Jul 26; 3(7):e18. PubMed ID: 23238290
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
    Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS.
    Clin Gastroenterol Hepatol; 2019 Dec 26; 17(13):2722-2730.e4. PubMed ID: 30448597
    [Abstract] [Full Text] [Related]

  • 6. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
    Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA.
    Aliment Pharmacol Ther; 2015 Jan 26; 41(1):54-64. PubMed ID: 25329562
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.
    Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW.
    Clin Gastroenterol Hepatol; 2009 Nov 26; 7(11):1189-94. PubMed ID: 19426836
    [Abstract] [Full Text] [Related]

  • 11. Managing bile acid diarrhoea.
    Walters JR, Pattni SS.
    Therap Adv Gastroenterol; 2010 Nov 26; 3(6):349-57. PubMed ID: 21180614
    [Abstract] [Full Text] [Related]

  • 12. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.
    Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M.
    Gut; 2015 Jan 26; 64(1):84-92. PubMed ID: 24727487
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.
    Borup C, Wildt S, Rumessen JJ, Bouchelouche PN, Graff J, Damgaard M, McQuitty C, Rainteau D, Munck LK.
    Aliment Pharmacol Ther; 2017 Jun 26; 45(11):1433-1442. PubMed ID: 28378364
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biomarkers for Bile Acid Malabsorption in Diarrhea-predominant Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
    Liu T, Ma M, Li K, Tan W, Yu H, Wang L.
    J Clin Gastroenterol; 2017 Jun 26; 57(5):451-458. PubMed ID: 36867517
    [Abstract] [Full Text] [Related]

  • 20. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
    Zweers SJ, de Vries EM, Lenicek M, Tolenaars D, de Waart DR, Koelfat KV, Groen AK, Olde Damink SW, Beuers U, Ponsioen C, Jansen PL, Schaap FG.
    Hepatol Int; 2017 Jan 26; 11(1):132-140. PubMed ID: 27696157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.